ReviewCurrent hypertension reports2007
Compliance and fixed-dose combination therapy.
Review in Current hypertension reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 67 citations in OpenAlex.
- Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.Journal of clinical hypertension (Greenwich, Conn.) · 2024Trial
- A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile.International journal of clinical practice · 2008Trial
- Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.Cardiovascular diabetology · 2007Trial
- Review
- 3D Printing of Pharmaceutical Application: Drug Screening and Drug Delivery.Pharmaceutics · 2021Review
- Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe.Frontiers in cardiovascular medicine · 2021Article
- Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review.Pharmaceutics · 2020Review
- Development of an entirely remote, non-physician led hypertension management program.Clinical cardiology · 2019Article
- Factors influencing adherence to treatment in older adults with hypertension.Clinical interventions in aging · 2018Article
- Hypertension in African Americans.Current cardiology reports · 2017Review
- Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Review
- The polypill approach - An innovative strategy to improve cardiovascular health in Europe.BMC pharmacology & toxicology · 2017Review
- Herbal Fixed Dose Combinations in Nepal: Growing Concerns in a Developing Country.Journal of clinical and diagnostic research : JCDR · 2016Article
- Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 Chinese patients with hypertension: an observational study.Advances in therapy · 2014Observational
- Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study.Journal of drug assessment · 2014Article
- Antihypertensive combination therapy in primary care offices: results of a cross-sectional survey in Switzerland.International journal of general medicine · 2014Article
- Phentermine and topiramate for the management of obesity: a review.Drug design, development and therapy · 2013Review
- Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination.Integrated blood pressure control · 2010Article
- Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study.Clinical drug investigation · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite data on the importance of blood pressure control in preventing cardiovascular and cerebrovascular events, only 34% of hypertensive patients have their blood pressure under control. The National Council on Patient Information and Education has estimated that the compliance rate is just over 30% for chronic conditions like hypertension. Polypharmacy and complex treatment regimens have been identified as important, modifiable risk factors for medication noncompliance. Fixed-dose combination regimens are attractive options because of the improved antihypertensive efficacy resulting from the dual mechanistic action of components targeting different effector mechanisms. One drug in the fixed-dose combination may negate an adverse effect of the other medication. Above all, fixed-dose combination therapy reduces pill burden and improves medication compliance, which can translate into better cardiovascular outcomes. Fixed-dose combinations should be used routinely for the management of hypertension and should also be considered when initiating therapy for patients with newly diagnosed hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.